MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
All
Ages:
18 years and above
Locations: Premier Surgery Center/Atrium Health Wake Forest Baptist, High Point, North Carolina +1536 locations
Conditions: Lumbar Spinal Stenosis
Register for Updates
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974
Recruiting
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Locations: Wake Forest Baptist Health - High Point Medical Center, High Point, North Carolina +93 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510
Recruiting
The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
All
Ages:
18 years and above
Locations: Peters Medical Research, High Point, North Carolina +176 locations
Conditions: Colitis, Ulcerative
Register for Updates
Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression
NCT03942419
Recruiting
This study evaluates the progression of myopia in participants using microdosed atropine 0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study medication daily in each eye for 48 months. Efficacy and safety assessments will be performed at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals for an additional year.
Gender:
All
Ages:
Between 3 years and 12 years
Locations: Wake Forest Health Network Ophthalmology - Oak Hollow, High Point, North Carolina +18 locations
Conditions: Myopia
Register for Updates
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
NCT03600701
Recruiting
This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cobimetinib is... Read More
Gender:
All
Ages:
18 years and above
Locations: Hayworth Cancer Center, High Point, North Carolina +17 locations
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, Metastatic Lung Non-Small Cell Carcinoma
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
NCT04609904
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Gender:
All
Ages:
Between 12 years and 80 years
Locations: Research Site, High Point, North Carolina +422 locations
Conditions: Asthma
Register for Updates
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
NCT05872256
Recruiting
The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to... Read More
Gender:
All
Ages:
18 years and above
Locations: Dermatology Consulting Services, PLLC, High Point, North Carolina
Conditions: Scalp Psoriasis
Register for Updates
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
NCT05432596
Recruiting
This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once daily or twice daily for 4 weeks.
Gender:
All
Ages:
Between 12 years and 65 years
Locations: Aclaris Investigational Site, High Point, North Carolina +29 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
NCT05679908
Recruiting
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with chronic migraine.
Gender:
All
Ages:
Between 18 years and 65 years
Locations: Peters Medical Research, High Point, North Carolina +24 locations
Conditions: Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Locations: Peters Medical Research, High Point, North Carolina +111 locations
Conditions: Lung Cancer
Register for Updates
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
NCT05071716
Recruiting
Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
Gender:
All
Ages:
Between 18 years and 85 years
Locations: Bausch Site 160, High Point, North Carolina +98 locations
Conditions: Hepatic Encephalopathy
Register for Updates
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day
NCT04971109
Recruiting
This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered BID for 28 days in adult subjects.
Gender:
All
Ages:
Between 18 years and 80 years
Locations: High Point Clinical Trials Center, High Point, North Carolina +8 locations
Conditions: Smallpox
Register for Updates